Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer
Background and objective Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for use...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2009-03-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2009.03.006&path%5B%5D=250 |
| _version_ | 1811199141294899200 |
|---|---|
| author | Wei WU Liyan XU Zhe LIU Yunzhong ZHU Heling SHI Junfang TANG Zan LIU Qiyi MENG Lili GUO Hong TAO Mingzhi LI |
| author_facet | Wei WU Liyan XU Zhe LIU Yunzhong ZHU Heling SHI Junfang TANG Zan LIU Qiyi MENG Lili GUO Hong TAO Mingzhi LI |
| author_sort | Wei WU |
| collection | DOAJ |
| description | Background and objective Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for use in combination withcarboplatin and paclitaxel for the initial treatment of patients with unresectable, locally advanced, recurrent, or metastatic,nonsquamous, non-small cell lung cancer (NSCLC). The aim of this study is to observe the safety of bevacizumab therapy in combination with chemotherapy in Chinese patients with NSCLC. Methods Patients with advanced non-squamous NSCLC were treated with Bevacizumab 15 mg/kg, d1, repeated every 21 days until PD; Plus paclitaxel 175 mg/m2, on dl and carboplatin AUC=6 on dl. The cycle was repeated every 21 days. Results One grade 3 epistaxis was observed in onepatient. One grade 4 thrombosis was observed in one patient. 3/4-grade epistaxis and thrombosis was the most significant adverse events. Other adverse effects, such as hemoptysis, hypertension and proteinuria, were not severe and could be well tolerated. Conclusion Most chemotherapy-naive patients with advanced non-squamous NSCLC treated with bevacizumab in combination with paclitaxel and carboplatin have little adverse effects that can be well tolerated. |
| first_indexed | 2024-04-12T01:42:57Z |
| format | Article |
| id | doaj.art-844b5409074c44e7a8668aecfc07b81f |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-04-12T01:42:57Z |
| publishDate | 2009-03-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-844b5409074c44e7a8668aecfc07b81f2022-12-22T03:53:08ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872009-03-01123231235Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung CancerWei WULiyan XUZhe LIUYunzhong ZHUHeling SHIJunfang TANGZan LIUQiyi MENGLili GUOHong TAOMingzhi LIBackground and objective Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for use in combination withcarboplatin and paclitaxel for the initial treatment of patients with unresectable, locally advanced, recurrent, or metastatic,nonsquamous, non-small cell lung cancer (NSCLC). The aim of this study is to observe the safety of bevacizumab therapy in combination with chemotherapy in Chinese patients with NSCLC. Methods Patients with advanced non-squamous NSCLC were treated with Bevacizumab 15 mg/kg, d1, repeated every 21 days until PD; Plus paclitaxel 175 mg/m2, on dl and carboplatin AUC=6 on dl. The cycle was repeated every 21 days. Results One grade 3 epistaxis was observed in onepatient. One grade 4 thrombosis was observed in one patient. 3/4-grade epistaxis and thrombosis was the most significant adverse events. Other adverse effects, such as hemoptysis, hypertension and proteinuria, were not severe and could be well tolerated. Conclusion Most chemotherapy-naive patients with advanced non-squamous NSCLC treated with bevacizumab in combination with paclitaxel and carboplatin have little adverse effects that can be well tolerated.http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2009.03.006&path%5B%5D=250BevacizumabLung neoplasmsSafety |
| spellingShingle | Wei WU Liyan XU Zhe LIU Yunzhong ZHU Heling SHI Junfang TANG Zan LIU Qiyi MENG Lili GUO Hong TAO Mingzhi LI Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer Chinese Journal of Lung Cancer Bevacizumab Lung neoplasms Safety |
| title | Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer |
| title_full | Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer |
| title_fullStr | Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer |
| title_full_unstemmed | Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer |
| title_short | Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer |
| title_sort | acceptable safety of bevacizumab therapy in combination with chemotherapy in patients with advanced lung cancer |
| topic | Bevacizumab Lung neoplasms Safety |
| url | http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2009.03.006&path%5B%5D=250 |
| work_keys_str_mv | AT weiwu acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT liyanxu acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT zheliu acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT yunzhongzhu acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT helingshi acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT junfangtang acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT zanliu acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT qiyimeng acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT liliguo acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT hongtao acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer AT mingzhili acceptablesafetyofbevacizumabtherapyincombinationwithchemotherapyinpatientswithadvancedlungcancer |